US Allows Science and Technology Agreement with China to Expire, Pointing to Deepening R&D Competition
The US-China Science and Technology Agreement (STA), a pivotal accord initially inked in 1979 by...
Novartis Builds Two Radioligand Therapy Facilities in U.S. to Expand Cancer Treatment Capabilities
Novartis AG (NYSE: NVS), a Swiss pharmaceutical giant listed on the NYSE under the ticker...
Jiangsu Suzhou Launches $843 Million Biomedicine Fund to Boost Pharma and Medical Device Innovation
The Jiangsu Suzhou Biomedicine Industry Special Fund of Fund (FoF), a colossal pharmaceutical investment vehicle...
Sage Group Expands into China’s Healthcare Market with Cenponts Healthcare Partnership
Sage Group, a UK-based financial advisory powerhouse, has announced a strategic foray into China’s burgeoning...
Hanx Biopharmaceuticals Receives NMPA Approval for HX009 Combination Therapy Phase II Trial
On September 5, 2024, China-based Hanx Biopharmaceuticals Co., Ltd announced that it has received approval...
E-commerce and Physical Stores to Stock Hanmi’s OTC Drugs Following Shanghai Pharma Deal
Hanmi Pharmaceutical, a leading South Korean pharmaceutical company, has reportedly entered into a supply agreement...
Aspen Pharmacare’s 2024 Fiscal Report Shows Mixed Results Amid China’s VBP Impact
Aspen Pharmacare Holdings Ltd (JSE: APN), a leading South African pharmaceutical company, has reported its...
European Commission Approves Merck’s Keytruda-Padcev Combo for First-Line Urothelial Carcinoma Treatment
Merck & Co., Inc. (NYSE: MRK), a global healthcare leader based in the United States,...
Manufacturing Challenges for Novo Nordisk’s Ozempic Impact Diabetes and Obesity Treatments in Europe
Novo Nordisk (NYSE: NVO), a leading Danish pharmaceutical company, has released a joint statement with...
Skyline Therapeutics’ Gene Therapy Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
Skyline Therapeutics, a biopharmaceutical company based in China, has received Orphan Drug Designation (ODD) from...
CGeneTech Secures RMB 100 Million in Series C Financing to Advance Drug Commercialization and Clinical Pipeline
CGeneTech (Suzhou, China) Co., Ltd., a biopharmaceutical company based in China, has reportedly secured a...
Innovent Biologics’ IBI363 Earns FDA Fast-Track Designation for Advanced Melanoma Treatment
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has received fast-track...
Jafron Biomedical’s Blood Purification Devices Gain EU Market Approval Under MDR
Jafron Biomedical Co., Ltd, a prominent player in the blood purification sector based in China,...
China’s 13 Ministries Unite to Chart a Healthier Future for Rural Communities
China’s National Health Commission (NHC), in collaboration with the National Development and Reform Commission, Ministry...
Humanwell Healthcare’s Innovative Drug for Solid Tumors Gets Green Light from NMPA
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a leading pharmaceutical entity in China, has received...
Jiangsu Hengrui and Chongqing Genrix Launch Anti-IL-17 Therapies for Psoriasis in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) and Chongqing Genrix Biopharmaceutical Co., Ltd, two leading...
China Unveils Blueprint for Service Trade Expansion through Strategic Opening Up
China’s State Council has issued a strategic directive titled “Opinions on Promoting the High-quality Development...
China’s NHC Charts Ambitious Healthcare Reform Path with Emphasis on TCM and Technology
Lei Haichao, Director of China’s National Health Commission (NHC), has outlined a comprehensive reform agenda...
EpimAb’s EMB-06 Secures $635 Million Licensing Agreement with Vignette for Multiple Myeloma Therapy
EpimAb Biotherapeutics, a Shanghai-based biotech firm, has inked a licensing deal with Vignette for the...
Sanofi’s Tolebrutinib Shows Mixed Results in Phase III Multiple Sclerosis Trials
PARIS—French pharmaceutical giant Sanofi (NASDAQ: SNY) has reported mixed outcomes from three Phase III trials...